China Never Patented Remdesivir; Where the CDC and WHO Disagree on Asymptomatic Carriers
investigativeeconomics.substack.com
In February, the Wuhan Institute of Virology announced that it would patent the COVID-19 drug remdesivir, which was originally developed by the U.S. company Gilead Sciences as a treatment for Ebola. The institute had been studying the disease that was ravaging Wuhan province and they focused on two potential drugs that were “highly effective”: remdesivir and the anti-malarial chloroquine. In the announcement, they noted that they would not seek a patent on chloroquine.
China Never Patented Remdesivir; Where the CDC and WHO Disagree on Asymptomatic Carriers
China Never Patented Remdesivir; Where the…
China Never Patented Remdesivir; Where the CDC and WHO Disagree on Asymptomatic Carriers
In February, the Wuhan Institute of Virology announced that it would patent the COVID-19 drug remdesivir, which was originally developed by the U.S. company Gilead Sciences as a treatment for Ebola. The institute had been studying the disease that was ravaging Wuhan province and they focused on two potential drugs that were “highly effective”: remdesivir and the anti-malarial chloroquine. In the announcement, they noted that they would not seek a patent on chloroquine.